28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
STOPP criteria PIMs, unlike Beers criteria PIMs, are significantly associated with avoidable ADEs in older people that cause or contribute to urgent hospitalization. 5 key findings →
Participants: 600 Evidence: low
Full summary, score breakdown and related studies → Original source
By using fluorine 18 fluorodeoxyglucose PET of the brain, a deep learning algorithm developed for early prediction of Alzheimer disease achieved 82% specificity at 100% sensitivity, an average of 75.8 months prior to the final diagnosis. © RSNA, 2018 Online supplemental material is available for this article. 3 key findings →
Participants: 1,002 Evidence: low
Full summary, score breakdown and related studies → Original source
We built and validated a deep learning algorithm predicting the individual diagnosis of Alzheimer's disease (AD) and mild cognitive impairment who will convert to AD (c-MCI) based on a single cross-sectional brain structural MRI scan. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
The precise mechanisms that lead to cognitive decline in Alzheimer's disease are unknown. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Astrocytes are crucial to brain homeostasis, yet their changes along the spatiotemporal progression of Alzheimer's disease (AD) neuropathology remain unexplored. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In the field of computer-aided Alzheimer's disease (AD) diagnosis, jointly identifying brain diseases and predicting clinical scores using magnetic resonance imaging (MRI) have attracted increasing attention since these two tasks are highly correlated. 1 key finding →
Participants: 1,984 Evidence: low
Full summary, score breakdown and related studies → Original source
Individuals with Down syndrome (DS) are more likely to experience earlier onset of multiple facets of physiological aging. 3 key findings →
Participants: 46 Evidence: low
Full summary, score breakdown and related studies → Original source
The incidence of hip fracture appears to be associated with benzodiazepine use. 3 key findings →
Participants: 125 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Community-based, commercially insured, older adults with probable dementia are more likely to take anticholinergics than matched controls. 2 key findings →
Participants: 418 Evidence: low
Full summary, score breakdown and related studies → Original source
More than half of nursing home residents suffer from dementia, which is about 19-fold higher than the prevalence in insured living in the community. 1 key finding →
Participants: 213,694 Evidence: low
Full summary, score breakdown and related studies → Original source
Admission trends show that new residents were older and had greater multimorbidity and limitations in physical functioning over time. 1 key finding →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Asthma, allergic rhinitis, and atopic dermatitis were significantly associated with increased risk of all-cause dementia and subtypes, with dose-effect relationships with the severity of allergic diseases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Language assessment has a crucial role in the clinical diagnosis of several neurodegenerative diseases. 5 key findings →
Participants: 61 Evidence: low
Full summary, score breakdown and related studies → Original source
While post mortem studies have identified the major cell types and functional systems affected in Alzheimer's disease (AD) the initial sites and molecular characteristics of pathology are still unclear. 1 key finding →
Participants: 56 Evidence: low
Full summary, score breakdown and related studies → Original source
Epidemiological and experimental studies suggest that a disease-aggravating neuroinflammatory process is present at preclinical stages of Alzheimer's disease. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
This study was designed to provide information on the prevalence and nature of psychiatric disorders in 497 individuals with Down syndrome. 1 key finding →
Participants: 497 Evidence: low
Full summary, score breakdown and related studies → Original source
Mild cognitively impaired patients with memory plus other cognitive domain deficits, rather than those with pure amnestic MCI, constituted the high-risk group. 1 key finding →
Participants: 108 Evidence: low
Full summary, score breakdown and related studies → Original source
As the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Nonrigid image registration is an important, but time-consuming task in medical image analysis. 1 key finding →
Participants: 299 Evidence: low
Full summary, score breakdown and related studies → Original source
Proneness to experience psychological distress is a risk factor for AD, an effect independent of AD pathologic markers such as cortical plaques and tangles. 3 key findings →
Participants: 140 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma phosphorylated tau (p-tau) and glial fibrillary acidic protein (GFAP) both reflect early changes in Alzheimer's disease (AD) pathology. 3 key findings →
Participants: 88 Evidence: low
Full summary, score breakdown and related studies → Original source
All markers tracked neuropathological severity, with BD p-tau217 having larger fold-changes than p-tau217 but BD p-tau217/Aβ42 enhancing this further. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma p-tau217 was 57% higher in subjects with at least one APOE ε4 allele, increased with age, was higher in males, and negatively correlated with brain volume measures by magnetic resonance imaging. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The assay demonstrated strong analytical performance, with repeatability and intermediate precision (%CV < 7%) and an LLoQ of 0.12 pg/mL. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Movement disorders have been carefully clinically defined, based on clinico-pathological series; however there is often diagnostic and prognostic uncertainty, especially in early stage disease. 1 key finding →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →